Related Experiment Video

Updated: May 31, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

OXPHOS toxicogenomics and Parkinson's disease

Ester López-Gallardo1, Ruth Iceta, Eldris Iglesias

  • 1Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain.

Mutation Research
|July 19, 2011
PubMed

Insights

Oxidative phosphorylation (OXPHOS) dysfunction is common in Parkinson's disease (PD). Both genetic mutations and environmental factors affecting OXPHOS, particularly mitochondrial DNA (mtDNA) encoded subunits, contribute to PD risk.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Parkinson's disease (PD) is frequently associated with reduced activity of oxidative phosphorylation (OXPHOS) complexes.
  • Mutations in nuclear genes and mitochondrial DNA (mtDNA) are implicated in PD pathogenesis and affect OXPHOS function.

Purpose of the Study:

  • To explore the complex interplay of genetic and environmental factors in PD, focusing on OXPHOS dysfunction.
  • To investigate the role of mtDNA-encoded subunits in PD pathogenesis and susceptibility to xenobiotics.

Main Methods:

  • Review of existing literature on PD genetics, OXPHOS, mtDNA, and environmental toxins.
  • Analysis of the mechanisms by which nuclear and mitochondrial factors, as well as xenobiotics, impact OXPHOS function in PD.

Main Results:

  • Both nuclear and mtDNA mutations can impair OXPHOS, leading to Parkinsonism.
  • Xenobiotics targeting OXPHOS complexes, particularly mtDNA-encoded subunits, can induce Parkinsonism.
  • PD rarely arises from single genetic or environmental causes; combined factors have additive effects on risk.

Conclusions:

  • The complexity of PD pathogenesis involves intricate interactions between nuclear and mitochondrial genetics and environmental exposures.
  • Further research into OXPHOS function is crucial for understanding PD etiology and developing effective treatments.

More Related Videos

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons09:21

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons

Published on: July 7, 2023

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...